- Home
- LPTX vs MRKR Comparison
LPTX vs MRKR Comparison
Compare LPTX & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- MRKR
- Stock Information
- Founded
- LPTX 2011
- MRKR N/A
- Country
- LPTX United States
- MRKR United States
- Employees
- LPTX N/A
- MRKR N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- LPTX Health Care
- MRKR Health Care
- Exchange
- LPTX Nasdaq
- MRKR Nasdaq
- Market Cap
- LPTX 11.1M
- MRKR 11.6M
- IPO Year
- LPTX N/A
- MRKR N/A
- Fundamental
- Price
- LPTX $0.31
- MRKR $0.95
- Analyst Decision
- LPTX Hold
- MRKR Strong Buy
- Analyst Count
- LPTX 1
- MRKR 3
- Target Price
- LPTX N/A
- MRKR $13.17
- AVG Volume (30 Days)
- LPTX 710.1K
- MRKR 2.7M
- Earning Date
- LPTX 11-12-2025
- MRKR 11-13-2025
- Dividend Yield
- LPTX N/A
- MRKR N/A
- EPS Growth
- LPTX N/A
- MRKR N/A
- EPS
- LPTX N/A
- MRKR N/A
- Revenue
- LPTX N/A
- MRKR $5,388,071.00
- Revenue This Year
- LPTX N/A
- MRKR N/A
- Revenue Next Year
- LPTX N/A
- MRKR $9.35
- P/E Ratio
- LPTX N/A
- MRKR N/A
- Revenue Growth
- LPTX N/A
- MRKR 44.55
- 52 Week Low
- LPTX $0.22
- MRKR $0.81
- 52 Week High
- LPTX $4.79
- MRKR $5.95
- Technical
- Relative Strength Index (RSI)
- LPTX 53.90
- MRKR 41.78
- Support Level
- LPTX $0.28
- MRKR $0.91
- Resistance Level
- LPTX $0.32
- MRKR $1.02
- Average True Range (ATR)
- LPTX 0.02
- MRKR 0.06
- MACD
- LPTX 0.00
- MRKR 0.02
- Stochastic Oscillator
- LPTX 73.33
- MRKR 63.16
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.